<![CDATA[FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer]]>
The FDA has cleared ArteraAI Breast, digital pathology-based risk stratification tool, for use among patients with early-stage, hormone receptor (HR)–positive, HER2-negative invasive breast cancer, according to a press release from the developer, Artera.1 …